Media coverage about Raptor Pharmaceutical Corp (NASDAQ:RPTP) has been trending positive on Monday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Raptor Pharmaceutical Corp earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.81590342763 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Raptor Pharmaceutical Corp (NASDAQ RPTP) opened at 9.00 on Monday.

TRADEMARK VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/10/09/raptor-pharmaceutical-corp-rptp-receives-daily-news-sentiment-score-of-0-27.html.

About Raptor Pharmaceutical Corp

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Insider Buying and Selling by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)

Receive News & Ratings for Raptor Pharmaceutical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp and related companies with MarketBeat.com's FREE daily email newsletter.